ARALEZ PHARMACEUTICALS INC. (ARLZ) financial statements (2020 and earlier)

Company profile

Business Address 7100 WEST CREDIT AVENUE, SUITE 101
MISSISSAUGA, ON L5N 0E4
State of Incorp. BC
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2018
TTM
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 2965 
Cash and cash equivalents 2965 
Receivables 1320 
Inventory, net of allowances, customer advances and progress billings 75 
Inventory 75 
Other undisclosed current assets 42 
Total current assets: 5392 
Noncurrent Assets
Property, plant and equipment 77 
Intangible assets, net (including goodwill) 392417 
Goodwill 8277 
Intangible assets, net (excluding goodwill) 310340 
Other noncurrent assets 11 
Total noncurrent assets: 401425 
TOTAL ASSETS: 453517 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 5241 
Accounts payable 249 
Accrued liabilities 2832 
Business combination, contingent consideration, liability 1110 
Other liabilities 46 
Total current liabilities: 6857 
Noncurrent Liabilities
Long-term debt and lease obligation 275274 
Long-term debt, excluding current maturities 275274 
Liabilities, other than long-term debt 9263 
Other liabilities 32 
Business combination, contingent consideration, liability 8961 
Other undisclosed noncurrent liabilities 43 
Total noncurrent liabilities: 370341 
Total liabilities: 438398 
Stockholders' equity
Stockholders' equity attributable to parent 151190
Common stock, share subscribed but unissued, subscriptions receivable   0
Additional paid in capital 3643520
Accumulated other comprehensive income 145 
Accumulated deficit (363)(238) 
Total stockholders' equity: 151190
TOTAL LIABILITIES AND EQUITY: 4535170

Income statement (P&L) ($ in millions)

3/31/2018
TTM
12/31/2017
12/31/2016
12/31/2015
Revenues
(Revenue, Net)
 10654 
Cost of revenue (84)(23) 
Cost of goods and services sold (34)(13) 
Gross profit: 2232 
Operating expenses (119)(134) 
Operating loss: (97)(103) 
Nonoperating income
(Other Nonoperating income)
 16 
Interest and debt expense (27)(0) 
Loss from continuing operations before equity method investments, income taxes: (123)(97) 
Other undisclosed loss from continuing operations before income taxes  (6) 
Loss from continuing operations before income taxes: (123)(103) 
Income tax expense (benefit) (2)0 
Net loss available to common stockholders, basic: (125)(103) 
Dilutive securities, effect on basic earnings per share (0)(5) 
Net loss available to common stockholders, diluted: (125)(108) 

Comprehensive Income ($ in millions)

3/31/2018
TTM
12/31/2017
12/31/2016
12/31/2015
Net loss: (125)(103) 
Comprehensive loss: (125)(103) 
Other undisclosed comprehensive income, net of tax, attributable to parent 95 
Comprehensive loss, net of tax, attributable to parent: (116)(98) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: